Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persisting Effects of Psilocybin
NCT02971605Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Johns Hopkins University. Primary endpoint: Amygdala Response to Stimuli in the Emotion Recognition Test. Started Jul 2017; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02971605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971605.